Opevesostat

Small molecule

Also known as MK-5684

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

Metastatic Castration-Resistant Prostate Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-05-10.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Metastatic Castration-Resistant Prostate Cancer
NCT06136650 · Merck Sharp & Dohme LLC
2023-12-18 – 2030-12-02 · Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
What this study did
Other / comorbidity
NCT06136624 · Merck Sharp & Dohme LLC
2023-12-31 – 2030-03-29 · Prostate Cancer Metastatic
What this study did
Phase 2 (1)
Other / comorbidity
NCT06979596 · Merck Sharp & Dohme LLC
2025-08-11 – 2027-11-04 · Malignant Neoplasm
What this study did
Phase 1/2 (3)
Metastatic Castration-Resistant Prostate Cancer
NCT07908524 · Merck Sharp & Dohme LLC
2026-12-14 – 2032-06-29 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT06353386 · Merck Sharp & Dohme LLC
2024-05-20 – 2029-01-15 · Prostatic Neoplasms, Castration-Resistant
What this study did
Other / comorbidity
NCT06863272 · Merck Sharp & Dohme LLC
2025-07-03 – 2031-10-01 · Castration-Resistant Prostatic Cancer, Metastasis
What this study did
Phase 1 (8)
Metastatic Castration-Resistant Prostate Cancer
NCT06104449 · Merck Sharp & Dohme LLC
2023-11-14 – 2026-04-17 · Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT06136598 · Merck Sharp & Dohme LLC
2024-01-30 – 2026-03-09 · Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
What this study did
Other / comorbidity
NCT07548606 · Merck Sharp & Dohme LLC
2026-05-11 – 2026-06-18 · Healthy
What this study did
NCT06860243 · Merck Sharp & Dohme LLC
2025-05-13 – 2026-02-19 · Hepatic Impairment, Healthy Participants
What this study did
NCT06814132 · Merck Sharp & Dohme LLC
2025-04-07 – 2025-10-14 · Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
What this study did
NCT06633419 · Merck Sharp & Dohme LLC
2024-12-18 – 2025-05-13 · Healthy
What this study did
NCT06566989 · Merck Sharp & Dohme LLC
2024-09-19 – 2024-10-17 · Metastatic Prostate Cancer
What this study did
NCT06554639 · Merck Sharp & Dohme LLC
2024-07-11 – 2024-08-29 · Prostatic Neoplasms
What this study did

Competitive landscape

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Opevesostat: this drugPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
FluzoparibPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
MevrometostatPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Zadavotide GuraxetanPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
LuxdegalutamidePhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
AKY-2519Phase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Opevesostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
Phase 3Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2028-05-10 · NCT06136650 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Prostate Cancer MetastaticRecruiting
Est. primary completion 2028-11-30 · NCT06136624 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 1/2Castration-Resistant Prostatic Cancer, MetastasisRecruiting
Est. primary completion 2031-10-01 · NCT06863272 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 1/2Metastatic Castration-Resistant Prostate CancerNot yet recruiting
Est. primary completion 2032-06-29 · NCT07908524 · CT.gov ↗
What to watch

See the full readout calendar ↗